Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS



Share on StockTwits

Council for Federal Cannabis Regulation (CFCR) Praises Enactment of H.R. 8454, "The Medical Marijuana and Cannabidiol Research Expansion Act," Signed into Law By President Biden

Passage Will Accelerate Much-Needed Research on the Therapeutic Benefits and Potential Risks To Public Health and Safety, Advancing the Goal of Establishing a Well-Regulated Pathway Forward for the Cannabis Industry

 

WASHINGTON, D.C. - December 13, 2022 (Investorideas.com Newswire) The Council for Federal Cannabis Regulation (CFCR) today issued a statement widely applauding the enactment of the new "Medical Marijuana and Cannabidiol Research Expansion Act," H.R. 8454, signed into law by President Biden on December 2, 2022

"On behalf of 16 partner organizations, each of which is committed to various forms of research in their ongoing battles against life threatening and debilitating ailments, we congratulate Senators Dianne Feinstein (D-CA), Chuck Grassley (R-IA), and Brian Schatz (D-HI), and Representatives Earl Blumenauer (D-OR) and Andy Harris (R-MD) for their bipartisan leadership in securing Congressional passage of this historic measure," said CFCR Board Chair, Sheri Orlowitz. "Passage of this bill will accelerate medical research into the risks and therapeutic benefits of this complex plant and its derivatives and ensure that physicians can discuss marijuana and CBD use with their patients.

"Without reservation, CFCR looks forward to working with the Biden Administration as it implements this important new law."

Passage of this legislation is a major step forward in federal regulatory policy with respect to cannabis. CFCR Executive Director Deborah Johnson explained,"As the Biden Administration considers whether to change the Schedule I status of marijuana under the Controlled Substances Act of 1970 (CSA), it is crucial that federal regulators have available sufficient scientific evidence to inform the most appropriate classification for cannabis, if any is needed under the Controlled Substances Act. While the 2018 Farm Bill made important strides by de-scheduling cannabidiol (CBD), CBD is only one of more than 100 cannabinoids that scientists have identified in the marijuana plant, along with tetrahydrocannabinol (THC), the cannabinoid associated with intoxicating effects."

In addition to the numerous cannabinoids found in the plant, scientists have identified a broad range of other chemical substances such as flavonoids and terpenes. "CFCR's scientific experts have been working to advance regulators' understanding of the risks and benefits of cannabis, and we're incredibly pleased by the passage of legislation that will expedite much-needed research that can benefit patients throughout the country."

Despite the fact that millions of people with disabilities and chronic conditions worldwide use medical cannabis to treat their symptoms, it's common knowledge that both the risks and benefits vary greatly depending on the both the nature of the product they consume and conditions they seek to treat. "This bill will facilitate long-overdue domestic research into the potential therapeutic benefits and harms of medical cannabis," Johnson said.

CFCR supports breaking down the barriers to research to help the world better understand the potential therapeutic benefits of medical cannabis as well as potential risks. This will allow research institutions to manufacture, obtain, store, process, and dispense cannabis for academic purposes on a more expeditious basis and without risking federal funding. It will also allow them to conduct research on a wider range of cannabis, and encourages DEA to register more growers and increase efforts to ensure that researchers have an adequate and uninterrupted supply of marijuana for studies and clinical trials .. Finally, the bill clarifies that physicians can discuss the potential harms and benefits of cannabis with their patients without violating the Controlled Substances Act.

In addition to CFCR, organizations that supported these reforms to federal law governing cannabis research s included the Epilepsy Foundation, the American Academy of Neurology, the American Heart Association, the Autistic Self Advocacy Network, the Autistic Women & Nonbinary Network, the Brain Injury Association of America, the Hemophilia Federation of America, the Lupus Foundation of America, the National Eczema Association, the National Multiple Sclerosis Society, the National Organization for Tardive Dyskinesia, the National Psoriasis Foundation, Research!America, The Arc of the United States and The Michael J. Fox Foundation for Parkinson's Research.

For additional information, please visit uscfcr.org.

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow Us on StockTwits


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories for Cannabis stocks and Psychedelic Stocks

Buy a cannabis guest post on Investorideas.com









About Investorideas.com

https://www.investorideas.com/About/

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp